MX2015017881A - Método para el tratamiento y/o prevención contra encefalopatía traumática crónica grado ii. - Google Patents
Método para el tratamiento y/o prevención contra encefalopatía traumática crónica grado ii.Info
- Publication number
- MX2015017881A MX2015017881A MX2015017881A MX2015017881A MX2015017881A MX 2015017881 A MX2015017881 A MX 2015017881A MX 2015017881 A MX2015017881 A MX 2015017881A MX 2015017881 A MX2015017881 A MX 2015017881A MX 2015017881 A MX2015017881 A MX 2015017881A
- Authority
- MX
- Mexico
- Prior art keywords
- preventing
- treating chronic
- chronic traumatic
- traumatic encephalopathy
- piperazin
- Prior art date
Links
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 title abstract 2
- 208000017004 dementia pugilistica Diseases 0.000 title abstract 2
- 229960003966 nicotinamide Drugs 0.000 abstract 1
- 235000005152 nicotinamide Nutrition 0.000 abstract 1
- 239000011570 nicotinamide Substances 0.000 abstract 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a un método para la prevención y/o tratamiento con la encefalopatía traumática crónica al administrarle a un sujeto N-(3,5-Bis-trifluorometil-bencil)-N-meti l-6-(piperazin-1-il)-4-o-tolil nicotinamida o sus derivados de 4-alquil-piperazin-1-ilo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013902457A AU2013902457A0 (en) | 2013-07-02 | Method for preventing and/or treating chronic traumatic encephalopathy - ii | |
| PCT/AU2014/050108 WO2015000033A1 (en) | 2013-07-02 | 2014-07-02 | Method for preventing and/or treating chronic traumatic encephalopathy-ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015017881A true MX2015017881A (es) | 2016-09-14 |
Family
ID=52142942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015017881A MX2015017881A (es) | 2013-07-02 | 2014-07-02 | Método para el tratamiento y/o prevención contra encefalopatía traumática crónica grado ii. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20160136160A1 (es) |
| EP (1) | EP3016657B1 (es) |
| JP (1) | JP6464421B2 (es) |
| KR (1) | KR101903713B1 (es) |
| CN (1) | CN105358153A (es) |
| AU (2) | AU2014286926A1 (es) |
| BR (1) | BR112015032534B1 (es) |
| CA (1) | CA2914523A1 (es) |
| HK (2) | HK1220639A1 (es) |
| IL (1) | IL242898B (es) |
| MX (1) | MX2015017881A (es) |
| NZ (1) | NZ714708A (es) |
| RU (1) | RU2674653C2 (es) |
| SG (1) | SG11201509855VA (es) |
| WO (1) | WO2015000033A1 (es) |
| ZA (1) | ZA201508872B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020008137A (es) * | 2018-02-02 | 2020-10-19 | Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro | Formulaciones orales y usos de las mismas. |
| EP3746077A4 (en) * | 2018-02-02 | 2021-10-27 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | PARENTERAL FORMULATIONS AND USES THEREOF |
| CA3149980A1 (en) * | 2019-08-23 | 2021-03-04 | Pierre Vankan | Therapeutic methods and uses thereof |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303790B1 (en) | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
| AUPQ514600A0 (en) * | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
| US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
-
2014
- 2014-07-02 JP JP2016522141A patent/JP6464421B2/ja active Active
- 2014-07-02 NZ NZ714708A patent/NZ714708A/en unknown
- 2014-07-02 KR KR1020167000309A patent/KR101903713B1/ko active IP Right Grant
- 2014-07-02 BR BR112015032534-3A patent/BR112015032534B1/pt active IP Right Grant
- 2014-07-02 US US14/902,228 patent/US20160136160A1/en not_active Abandoned
- 2014-07-02 RU RU2016103098A patent/RU2674653C2/ru active
- 2014-07-02 SG SG11201509855VA patent/SG11201509855VA/en unknown
- 2014-07-02 CN CN201480038316.8A patent/CN105358153A/zh active Pending
- 2014-07-02 CA CA2914523A patent/CA2914523A1/en not_active Abandoned
- 2014-07-02 WO PCT/AU2014/050108 patent/WO2015000033A1/en active Application Filing
- 2014-07-02 EP EP14819550.6A patent/EP3016657B1/en active Active
- 2014-07-02 AU AU2014286926A patent/AU2014286926A1/en not_active Abandoned
- 2014-07-02 MX MX2015017881A patent/MX2015017881A/es unknown
-
2015
- 2015-12-03 ZA ZA2015/08872A patent/ZA201508872B/en unknown
- 2015-12-03 IL IL242898A patent/IL242898B/en active IP Right Grant
-
2016
- 2016-07-25 HK HK16108842.5A patent/HK1220639A1/zh unknown
- 2016-08-15 HK HK16109746.0A patent/HK1221637A1/zh unknown
-
2019
- 2019-10-31 AU AU2019257499A patent/AU2019257499A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016103098A (ru) | 2017-08-03 |
| RU2674653C2 (ru) | 2018-12-12 |
| EP3016657A1 (en) | 2016-05-11 |
| CA2914523A1 (en) | 2015-01-08 |
| RU2016103098A3 (es) | 2018-06-19 |
| AU2014286926A1 (en) | 2015-12-17 |
| WO2015000033A1 (en) | 2015-01-08 |
| KR101903713B1 (ko) | 2018-10-04 |
| CN105358153A (zh) | 2016-02-24 |
| EP3016657B1 (en) | 2019-06-26 |
| EP3016657A4 (en) | 2017-03-22 |
| NZ714708A (en) | 2019-06-28 |
| JP6464421B2 (ja) | 2019-02-06 |
| SG11201509855VA (en) | 2016-01-28 |
| HK1221637A1 (zh) | 2017-06-09 |
| IL242898B (en) | 2020-06-30 |
| AU2019257499A1 (en) | 2019-11-21 |
| KR20160029066A (ko) | 2016-03-14 |
| JP2016523262A (ja) | 2016-08-08 |
| BR112015032534A2 (pt) | 2017-07-25 |
| ZA201508872B (en) | 2017-08-30 |
| HK1220639A1 (zh) | 2017-05-12 |
| US20160136160A1 (en) | 2016-05-19 |
| BR112015032534B1 (pt) | 2020-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| MX2018013983A (es) | Inhibidores g12c de kras. | |
| TN2017000544A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| PH12015502091A1 (en) | Cdc7 inhibitors | |
| MX2017014191A (es) | Metodos de tratamiento de una enfermedad neurodegenerativa. | |
| PH12018500446A1 (en) | Pyridinone dicarboxamide for use as bromodomain inhibitors | |
| MX2020011818A (es) | Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos. | |
| TW201713333A (en) | Methods of treating a neurodegenerative disease | |
| MX2017001352A (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). | |
| PH12016501751A1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| TN2016000107A1 (en) | Substituted phenylalanine derivatives | |
| GEP20186871B (en) | Benzamide and nicotinamide compounds and methods of using same | |
| PH12017500348B1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
| IN2013MU03862A (es) | ||
| MX2015017881A (es) | Método para el tratamiento y/o prevención contra encefalopatía traumática crónica grado ii. | |
| PH12016501173A1 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
| EA201791099A1 (ru) | Хинолин карбоксамиды для применения в лечении лейкоза | |
| AU2019257493A1 (en) | Method for preventing and/or treating chronic traumatic encephalopathy-I | |
| PH12017501735A1 (en) | Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same | |
| PH12016502322A1 (en) | Compounds and methods for preventing or treating malaria | |
| MX2016000037A (es) | Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
| MX2019005723A (es) | Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo. | |
| MX2017005669A (es) | Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos. | |
| MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
| PL397383A1 (pl) | Nowe pochodne oktahydropirazyno[2,1-a:5,4-a']diizochinoliny i ich zastosowanie |